BR9703624A - Combinação formulação farmacêutica processo para o tratamento de depressão em um animal uso de mirtazapina uso de um ou mais srri's e embalagem - Google Patents

Combinação formulação farmacêutica processo para o tratamento de depressão em um animal uso de mirtazapina uso de um ou mais srri's e embalagem

Info

Publication number
BR9703624A
BR9703624A BR9703624A BR9703624A BR9703624A BR 9703624 A BR9703624 A BR 9703624A BR 9703624 A BR9703624 A BR 9703624A BR 9703624 A BR9703624 A BR 9703624A BR 9703624 A BR9703624 A BR 9703624A
Authority
BR
Brazil
Prior art keywords
srri
mirtazapine
depression
packaging
treatment
Prior art date
Application number
BR9703624A
Other languages
English (en)
Inventor
Victor Johannes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9703624(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9703624A publication Critical patent/BR9703624A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9703624A 1996-06-19 1997-06-18 Combinação formulação farmacêutica processo para o tratamento de depressão em um animal uso de mirtazapina uso de um ou mais srri's e embalagem BR9703624A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
BR9703624A true BR9703624A (pt) 1998-09-01

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9703624A BR9703624A (pt) 1996-06-19 1997-06-18 Combinação formulação farmacêutica processo para o tratamento de depressão em um animal uso de mirtazapina uso de um ou mais srri's e embalagem

Country Status (24)

Country Link
US (1) US5977099A (pt)
JP (2) JP4925074B2 (pt)
KR (1) KR100481254B1 (pt)
CN (1) CN1132581C (pt)
AR (1) AR007609A1 (pt)
AT (1) ATE213159T1 (pt)
AU (1) AU727851B2 (pt)
BR (1) BR9703624A (pt)
CA (1) CA2208199C (pt)
CZ (1) CZ290691B6 (pt)
DE (1) DE69710390T2 (pt)
DK (1) DK0813873T3 (pt)
ES (1) ES2172744T3 (pt)
HU (1) HU225534B1 (pt)
ID (1) ID17051A (pt)
IL (1) IL121076A (pt)
NO (1) NO313177B1 (pt)
NZ (1) NZ328113A (pt)
PL (1) PL188520B1 (pt)
PT (1) PT813873E (pt)
RU (1) RU2181287C2 (pt)
SG (1) SG60073A1 (pt)
TR (1) TR199700522A2 (pt)
ZA (1) ZA975335B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
WO1999025356A1 (en) * 1997-11-14 1999-05-27 Akzo Nobel N.V. Use of mirtazapine for treating sleep apneas
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
EP1251854A2 (en) * 2000-01-19 2002-10-30 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
EP1656937A1 (en) * 2000-02-11 2006-05-17 Akzo Nobel N.V. The use of mirtazapine for the treatment of sleep disorders
AU2002212888A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
AU2003274608A1 (en) * 2002-11-07 2004-06-07 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CA2516653A1 (en) * 2003-02-21 2004-09-10 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
ES2426915T3 (es) 2003-09-10 2013-10-25 Brentwood Equities Ltd. Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
CA2585317C (en) * 2004-11-19 2015-02-24 N.V. Organon Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102459769B (zh) 2009-06-09 2014-03-26 住友重机械工业株式会社 混合式挖土机及其控制方法
US8785453B2 (en) * 2009-11-13 2014-07-22 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
ES2062310T3 (es) * 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
AU750808B2 (en) * 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug

Also Published As

Publication number Publication date
JP4925074B2 (ja) 2012-04-25
NZ328113A (en) 1999-09-29
PL188520B1 (pl) 2005-02-28
AR007609A1 (es) 1999-11-10
SG60073A1 (en) 1999-02-22
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
CN1173330A (zh) 1998-02-18
KR980000447A (ko) 1998-03-30
JPH1067663A (ja) 1998-03-10
DE69710390D1 (de) 2002-03-21
US5977099A (en) 1999-11-02
HK1006081A1 (en) 1999-02-12
HU9701068D0 (en) 1997-08-28
CZ290691B6 (cs) 2002-09-11
IL121076A (en) 2000-10-31
ES2172744T3 (es) 2002-10-01
RU2181287C2 (ru) 2002-04-20
NO972816D0 (no) 1997-06-18
DK0813873T3 (da) 2002-05-27
HUP9701068A3 (en) 2000-07-28
HUP9701068A2 (hu) 1998-08-28
NO313177B1 (no) 2002-08-26
MX9704579A (es) 1998-07-31
DE69710390T2 (de) 2002-08-14
PL320628A1 (en) 1997-12-22
CA2208199A1 (en) 1997-12-19
AU2612997A (en) 1998-01-08
CZ187097A3 (cs) 1998-01-14
ZA975335B (en) 1998-01-26
PT813873E (pt) 2002-06-28
JP2009137970A (ja) 2009-06-25
TR199700522A3 (tr) 1998-01-21
TR199700522A2 (xx) 1998-01-21
CN1132581C (zh) 2003-12-31
AU727851B2 (en) 2001-01-04
KR100481254B1 (ko) 2005-09-12
ID17051A (id) 1997-12-04
CA2208199C (en) 2006-10-24
ATE213159T1 (de) 2002-02-15
NO972816L (no) 1997-12-22

Similar Documents

Publication Publication Date Title
EE03380B1 (et) Farmatseutiline aerosoolpreparaat ja selle valmistamismeetod
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
EE9900075A (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
CY2013003I2 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
ID21019A (id) Turunan pirazol, pembuatannya dan penggunaannya dalam sediaan farmasi
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
PT1003478E (pt) Preparacoes aquosas de aerossol contendo macromoleculas biologicamente activas e processo para a preparacao dos respectivos aerossois
FI971173L (fi) Laite ja menetelmät kuivien, jauhemaisten lääkkeiden annostelemiseksi
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
DE68905374D1 (de) Mittel zur vorbeugung und abhilfe gegen ischaemische verletzungen.
EE9700043A (et) Asendatud oksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
ITFI930247A0 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
BR9606992A (pt) Processo para o uso na construção de uma roupa e sistema de processamento
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
DE59610469D1 (de) Vorrichtung zur Verabreichung von Substanzen, insbesondere Inhalationspräparate
FI951468L (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
EE9600172A (et) Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid
FI962952L (fi) Delta 12,13-iso-taksolianalogit, niiden antineoplastinen käyttö ja niitä sisältävät farmaseuttiset koostumukset
NO982580L (no) Nye taxoider, deres fremstilling samt farmas°ystiske preparater inneholdende taxoidene
IT1277595B1 (it) Procedimento e dispositivo per l'introduzione di confezioni comprimibili in contenitori
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
BR9708093A (pt) Composto formulação uso composto e processo para tratamento de distúrbios mediados por 5-hidroxitriptamina e para preparação do composto
BR9506581A (pt) Composto composição farmacêutica uso do composto processo para a profilaxia ou tratamento de uma condição clínica em um manífero por exemplo um humano e para a preparação de um composto e composto intermediário
BR9710376A (pt) Composto antiviral uso do mesmo composi-Æo farmac-utica e processo para tratamento antiviral profil tico ou terap-utico de um animal humano ou nÆo humano
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, COM BASE NOS ARTIGOS 8O E 13 DA LPI